Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
441-460 of 653 trials

Advanced Solid Tumors: ALTA2618 Treatment

We are testing a new drug called ALTA2618 for patients with advanced solid tumors that have the AKT1 E17K mutation. The goal is to see how safe it is and how it affects tumor growth.

Advanced Solid Tumors with AKT1 E17K Mutation1-2 yearsSafety phase (I)Oncology

CHF10073 Inhaled Drug Study

We are evaluating the safety and absorption of the inhaled drug CHF10073 in healthy adults, both alone and with itraconazole. This study aims to understand how the drug behaves in the body.

Idiopathic Pulmonary Fibrosis1-2 yearsSafety phase (I)Internal MedicinePulmonology

Advanced Solid Tumors: ALE.P02 Treatment Study

We are investigating a new antibody-drug conjugate, ALE.P02, for adults with certain advanced solid tumors. The study aims to evaluate its safety and how well it may work against these tumors.

Advanced or Metastatic Squamous Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Decompensated Cirrhosis: New Human Albumin Solution

We are studying a new human albumin solution to see if it is safer and more effective than the standard treatment for patients with decompensated cirrhosis. This research aims to improve clinical outcomes for those needing long-term albumin therapy.

Decompensated Cirrhosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyInternal Medicine

Preventing Heart Issues in Cancer Patients: Empagliflozin Study

We are studying whether empagliflozin can help prevent heart problems in cancer patients undergoing chemotherapy with anthracyclines. We will compare its effects to a placebo to assess safety and effectiveness.

Cardiotoxicity1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyOncology

Advanced Solid Tumors: BMS986504 Study

We are investigating how the drug BMS986504 is processed in patients with advanced solid tumors that have a specific genetic deletion. This study may provide insights for future cancer treatments.

Malignant Solid Tumor1-2 yearsSafety phase (I)Oncology

Emicizumab Dosing in Congenital Hemophilia A Patients

We are studying whether personalized dosing of emicizumab can effectively prevent bleeding in patients with congenital hemophilia A compared to standard dosing. This trial also examines the impact on quality of life and treatment costs.

Hemophilia A1-2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Chronic Lymphocytic Leukemia: APG-2575 Study

We are studying a new medication, APG-2575, for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial will evaluate its safety and effectiveness alone and with other treatments.

Chronic Lymphocytic Leukemia (CLL)1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Advanced Cancers: AD-O51.4 Safety Study

We are evaluating the safety of a new investigational drug called AD-O51.4 for patients with advanced malignancies. This study aims to understand how well the drug is tolerated in this patient group.

Solid Tumor1-2 yearsSafety phase (I)Oncology

Ghrelin for Acute Ischemic Stroke Treatment

We are studying whether ghrelin can improve recovery in patients with acute ischemic stroke treated with endovascular thrombectomy. The trial will also assess its effects on overall health and safety over several days.

Ischemic Stroke1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology

Pain Management in Hernia Surgery: TAP Block vs. Local Infiltration

We are studying whether a TAP block offers better pain relief than local infiltration for patients after laparoscopic inguinal hernia repair. We also want to see if it leads to less need for pain medication.

Inguinal Hernia1-2 yearsMonitoring phase (IV)Standard MedicinesInternal MedicineOrthopedics and Traumatology

Niemann-Pick Type C and GM1/GM2 Gangliosidosis: Nizubaglustat Study

We are investigating how well nizubaglustat works and its safety for children with Niemann-Pick type C disease and GM1 or GM2 gangliosidosis. This study aims to see if it can improve movement and coordination compared to a placebo.

Niemann-Pick Type C Disease and GM1/GM2 Gangliosidoses1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesNeurologyPediatrics

V540A Vaccine Study in Healthy Adults

We are testing the V540A vaccine to see how it works in healthy adults. This study aims to evaluate its safety and effectiveness.

Human Papilloma Virus Infection1-2 yearsSafety phase (I)Infectious DiseasesOncology

Chronic Low Back Pain: Antibiotic Treatment Study

We are studying whether a three-month course of amoxicillin can help people with chronic low back pain and specific MRI changes. This trial compares the antibiotic treatment to a placebo to see if it offers any benefits.

Non-Specific Low Back Pain1-2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Vosoritide for Growth Issues in Children

We are studying a new treatment called vosoritide for children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome who haven't responded well to standard growth hormone therapy. The goal is to see if it helps improve their growth and is safe to use.

Turner SyndromeShort Stature Homeobox Gene MutationNoonan Syndrome1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyPediatrics

Hidradenitis Suppurativa: Brensocatib Study

We are testing a new medication, brensocatib, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it is more effective than a placebo in improving symptoms.

Hidradenitis Suppurativa1-2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Oligometastatic Peritoneal Gastric Cancer: PIPAC Treatment Study

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard chemotherapy helps patients with oligometastatic peritoneal gastric cancer have better surgery outcomes and longer survival.

Metastatic Gastric Adenocarcinoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Cardiac Arrest: Ketamine vs. Propofol Sedation

We are studying whether ketamine sedation can better protect the brain and improve survival compared to propofol in patients resuscitated from cardiac arrest. This trial looks at outcomes at discharge and 180 days later.

Out-of-Hospital Cardiac Arrest1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Graves' Disease: IMVT-1402 Treatment Study

We are studying a new treatment called IMVT-1402 for adults with Graves' disease. The aim is to see if it can improve thyroid hormone levels compared to a placebo.

Grave's Disease1-2 yearsEfficacy phase (II)Investigational MedicinesEndocrinology

Chronic Kidney Disease: Dapagliflozin and Balcinrenone Study

We are investigating how dapagliflozin, alone or with balcinrenone, affects kidney function and fluid balance in people over 50 with chronic kidney disease. This study aims to understand the potential benefits of these treatments on energy metabolism and urine concentration.

Stage 3 Chronic Kidney Disease1-2 yearsEfficacy phase (II)Investigational MedicinesEndocrinologyNephrology